The global sepsis treatment market is forecast to grow at an annual rate of 8.5 percent from USD 429 million in 2019 to USD 700 million in 2025. The public-private support for target study efforts, the rising prevalence of infectious diseases, the number of sepsis incidences, and the government programs to raise sepsis awareness are all expected to fuel the market growth over the forecast period for Sepsis Treatment products.
Get a free sample copy of this Research Report at https://www.vynzresearch.com/healthcare/sepsis-treatment-market/request-sample
Furthermore, the demand for antibiotic-resistant bacterial strains, rising rates of hospital-acquired infections, and the high prevalence of a variety of chronic diseases such as diabetes may all contribute to the growth of the sepsis treatment market. Low healthcare spending in low- and middle-income countries, a lack of public interest, and the advent of the generic industry have all slowed the development of the sepsis treatment industry.
The medical device industry in North America is well-established. The availability of well-developed healthcare infrastructure, widespread acceptance of advanced sepsis diagnostic technology by medical practitioners, rising sepsis incidences in the area, and technical advances in the field of sepsis diagnostics are all driving the demand in North America.
Hospital-acquired infections (HAIs) can cause sepsis, especially in the elderly, newborn babies, and people with chronic illnesses. Because of the high prevalence of chronic diseases like diabetes, hospital-acquired infections are becoming more common. Increased visits to intensive care hospitals often result in infections, which can lead to sepsis.
One of the major reasons expected to fuel demand for its diagnostics solutions is the outbreak of novel coronavirus (COVID-19) and the resulting rise in the risk of contracting sepsis. In Seattle, Washington, over 30% of COVID-19 patients had signs of liver damage in April2020, according to a study conducted by the Global Sepsis Alliance. About 75% of COVID-19 patients registered a depressed immune response.
Some of the key players in the global sepsis treatment market are Abbott, Pfizer Inc, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Adrenomed AG, AM-Pharma B.V., Johnson & Johnson, Amomed Pharma GmbH, Asahi Kasei Corporation, Endacea, Inc, Novartis, and more...
Source: VynZ Research
No comments:
Post a Comment